Progressive Supranuclear Palsy (PSP) is a rare but important neurodegenerative disorder. Understanding its epidemiology is crucial for healthcare planning, research prioritization, and clinical trial design. This page summarizes the current epidemiological knowledge of PSP, including prevalence, incidence, demographic patterns, and risk factors.
The evidence for environmental factors is limited but includes:
The Movement Disorder Society (MDS) PSP criteria recognize multiple clinical variants[3]:
| Phenotype | Frequency | Key Features |
|---|---|---|
| Richardson's syndrome (PSP-RS) | 40-50% | Classic presentation with vertical gaze palsy, falls |
| PSP with corticobasal syndrome (PSP-CBS) | 15-20% | Asymmetric rigidity, apraxia |
| PSP with progressive aphasia (PSP-PPA) | 5-10% | Language impairment as primary feature |
| PSP-parkinsonism (PSP-P) | 10-15% | Tremor, rigidity, Lewy body overlap |
| PSP-pure akinesia with gait freezing (PSP-PAGF) | 5-10% | Akinetic-rigid syndrome without gaze palsy |
| Others (PSP-C, PSP-PN) | 5-10% | Cerebellar, cerebellar/psychiatric variants |
Phenotype distribution varies by population[@psp2023; @burrell2016]:
Population-based autopsy studies provide critical validation of clinical phenotypes[4]:
The relationship between clinical phenotype and underlying tau pathology:
Fluid and imaging biomarkers increasingly predict neuropathology:
Prevalence estimates for Progressive Supranuclear Palsy (PSP) in Asia vary across countries but generally appear lower than Western estimates[1]. Japanese studies report prevalence of 5-18 per 100,000, with some regional variation. Chinese population studies are limited but suggest rates of 1-5 per 100,000, potentially reflecting genetic differences or underdiagnosis. Korean studies report similar prevalence to Western populations in urban centers, approximately 5-7 per 100,000.
Genetic studies in Asian populations have identified unique MAPT haplotypes and rare variants that may influence PSP risk differently than in European populations[2]. The H1 haplotype frequency differs between Asian and Western populations, potentially contributing to epidemiological differences.
Japan has the most comprehensive PSP epidemiology data in Asia. Studies from the 1990s-2000s documented prevalence rates of 5-18 per 100,000, with increasing rates in older age groups[3]. Japanese clinical series have characterized PSP presentation, noting similar clinical features to Western cohorts but potentially earlier onset age.
Chinese PSP research has expanded recently with population-based studies and genetic screening. Reported prevalence ranges from 1-5 per 100,000, though diagnostic expertise varies across regions[4]. Genetic studies have identified unique tau gene variants in Chinese PSP patients.
Limited epidemiological data exists for PSP in India. Case series from major medical centers suggest similar clinical presentation to Western populations, but population-based prevalence estimates are lacking. The genetic architecture differs, with distinct MAPT haplotype distributions.
PSP in African populations is significantly understudied. Available data consists primarily of case reports and small case series. The limited evidence suggests PSP may be underdiagnosed due to limited neurological expertise and diagnostic resources[5]. Genetic studies indicate different ancestral backgrounds influence tau gene variation.
Brazil and other Latin American countries have emerging PSP research programs. Prevalence estimates are limited but clinical observations suggest PSP occurs at rates comparable to Western populations in urban centers with adequate neurological services. Access to specialized care remains a significant barrier in rural areas.
Non-Western populations face several challenges in PSP diagnosis and care:
These factors contribute to potential underdiagnosis and delayed diagnosis in many regions[6].
PSP Epidemiology Consortium. Global PSP prevalence and incidence: systematic review and meta-analysis. Movement Disorders. 2023. ↩︎
Chen JA, et al. MAPT haplotype diversity across global populations. Neurology. 2022. ↩︎
Litvan I, et al. PSP diagnosis and management guidelines. Neurology. 2020. ↩︎
Burrell JR, et al. Progressive supranuclear palsy. Lancet Neurology. 2016. ↩︎